A STUDY OF DASATINIB VS. HIGH-DOSE IMATINIB (600 MG) IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WHO FAILED TO ACHIEVE COMPLETE CYTOGENETIC RESPONSE AFTER 3-18 MONTHS OF IMATINIB THERAPY: